These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 32362897)
1. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens. Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M Front Immunol; 2020; 11():659. PubMed ID: 32362897 [TBL] [Abstract][Full Text] [Related]
2. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity. Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570 [TBL] [Abstract][Full Text] [Related]
3. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM Front Immunol; 2020; 11():1804. PubMed ID: 32973756 [TBL] [Abstract][Full Text] [Related]
4. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888 [TBL] [Abstract][Full Text] [Related]
5. Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase. Kremer AN; Bausenwein J; Lurvink E; Kremer AE; Rutten CE; van Bergen CAM; Kretschmann S; van der Meijden E; Honders MW; Mazzeo D; Watts C; Mackensen A; Falkenburg JHF; Griffioen M Front Immunol; 2020; 11():381. PubMed ID: 32218783 [TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation. Fuchs KJ; Falkenburg JHF; Griffioen M Best Pract Res Clin Haematol; 2024 Jun; 37(2):101555. PubMed ID: 39098803 [TBL] [Abstract][Full Text] [Related]
7. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1. Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962 [TBL] [Abstract][Full Text] [Related]
8. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
9. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Ofran Y; Kim HT; Brusic V; Blake L; Mandrell M; Wu CJ; Sarantopoulos S; Bellucci R; Keskin DB; Soiffer RJ; Antin JH; Ritz J Clin Cancer Res; 2010 Mar; 16(5):1642-51. PubMed ID: 20160060 [TBL] [Abstract][Full Text] [Related]
10. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF Front Immunol; 2018; 9():3016. PubMed ID: 30619360 [TBL] [Abstract][Full Text] [Related]
11. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation. Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833 [TBL] [Abstract][Full Text] [Related]
12. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Terakura S; Murata M; Warren EH; Sette A; Sidney J; Naoe T; Riddell SR Transplantation; 2007 May; 83(9):1242-8. PubMed ID: 17496542 [TBL] [Abstract][Full Text] [Related]
13. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens. Fuchs KJ; van de Meent M; Honders MW; Khatri I; Kester MGD; Koster EAS; Koutsoumpli G; de Ru AH; van Bergen CAM; van Veelen PA; 't Hoen PAC; van Balen P; van den Akker EB; Veelken JH; Halkes CJM; Falkenburg JHF; Griffioen M Blood; 2024 May; 143(18):1856-1872. PubMed ID: 38427583 [TBL] [Abstract][Full Text] [Related]
14. Minor histocompatibility antigens: past, present, and future. Spierings E Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921 [TBL] [Abstract][Full Text] [Related]
15. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171 [TBL] [Abstract][Full Text] [Related]
16. Rapid Multiplex Genotyping of 20 HLA-A Romaniuk DS; Postovskaya AM; Khmelevskaya AA; Malko DB; Efimov GA Front Immunol; 2019; 10():1226. PubMed ID: 31275297 [TBL] [Abstract][Full Text] [Related]
17. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. Armistead PM; Liang S; Li H; Lu S; Van Bergen CA; Alatrash G; St John L; Hunsucker SA; Sarantopoulos S; Falkenburg JH; Molldrem JJ PLoS One; 2011; 6(8):e23217. PubMed ID: 21858034 [TBL] [Abstract][Full Text] [Related]
18. High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation. Morishima S; Kashiwase K; Matsuo K; Azuma F; Yabe T; Sato-Otsubo A; Ogawa S; Shiina T; Satake M; Saji H; Kato S; Kodera Y; Sasazuki T; Morishima Y; Haematologica; 2016 Apr; 101(4):491-8. PubMed ID: 26768690 [TBL] [Abstract][Full Text] [Related]
19. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction. van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556 [TBL] [Abstract][Full Text] [Related]